UCB develops biopharmaceutical treatments focused on neurological and immunological conditions. Its marketed products include Cimzia for autoimmune and inflammatory diseases such as rheumatoid arthritis and Crohn's disease, and epilepsy therapies including Vimpat, Briviact and Keppra, plus Neupro for Parkinson's disease. Headquartered in Belgium, the company pursues research and commercialization of specialist medicines on a global scale.
| Year | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| 2022 | 5,517 | — | 418 | — |
| 2023 | 5,252 | -4.8% | 343 | -17.9% |
| 2024 | 6,152 | 17.1% | 1,065 | 210.5% |
| 2025 | 7,741 | 25.8% | 1,558 | 46.3% |
All markets — KeepWinning global stock screener
Other companies on Euronext Brussels: Elia Group SA/NV (ELI), Lotus Bakeries NV (LOTB), D'Ieteren Group SA (DIE), Ackermans & Van Haaren NV (ACKB), Sofina Société Anonyme (SOF), Groupe Bruxelles Lambert SA (GBLB)